Cargando…
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
Autores principales: | Yang, Min, Zhang, Wenhao, Yu, Kang, Wang, Peng, Jiang, Hua, Chen, Linjun, Meng, Haitao, Weng, Yiqin, Tao, Rong, Huang, Xin, Xing, Chongyun, Wang, Huamao, Wan, Jiangbo, Wang, Shasha, Dai, Lihui, Hendrix, Amanda Y., Xiao, Jun, Wang, Wei, Ma, Hong, Hao, Siguo, Jin, Jie, Li, Zonghai, Jiang, Songfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335117/ https://www.ncbi.nlm.nih.gov/pubmed/35443566 http://dx.doi.org/10.3324/haematol.2022.280629 |
Ejemplares similares
-
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020) -
Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023) -
scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012) -
Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020) -
Nonspecificity in a nonimmune human scFv repertoire
por: Kelly, Ryan L., et al.
Publicado: (2017)